Henry Schein (NASDAQ:HSIC – Get Rating) had its price target reduced by Credit Suisse Group from $100.00 to $90.00 in a research note released on Wednesday, Benzinga reports. They currently have an outperform rating on the stock.
Other research analysts have also issued research reports about the stock. The Goldman Sachs Group lowered shares of Henry Schein from a buy rating to a neutral rating and reduced their price objective for the stock from $93.00 to $85.00 in a research note on Thursday, July 21st. William Blair reaffirmed a market perform rating on shares of Henry Schein in a research note on Tuesday, May 3rd. Stifel Nicolaus cut their price target on shares of Henry Schein from $90.00 to $80.00 in a research note on Friday, June 17th. Piper Sandler cut their price target on shares of Henry Schein from $100.00 to $96.00 in a research note on Tuesday. Finally, StockNews.com lowered shares of Henry Schein from a strong-buy rating to a buy rating in a research note on Tuesday, July 19th. One research analyst has rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, Henry Schein has an average rating of Hold and an average price target of $87.14.
Henry Schein Stock Up 1.7 %
Henry Schein stock opened at $75.38 on Wednesday. The company’s 50 day simple moving average is $77.98 and its 200 day simple moving average is $81.97. Henry Schein has a fifty-two week low of $70.25 and a fifty-two week high of $92.68. The firm has a market capitalization of $10.26 billion, a price-to-earnings ratio of 16.18, a PEG ratio of 2.00 and a beta of 0.75. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.83 and a quick ratio of 0.91.
Insider Transactions at Henry Schein
In other news, EVP Gerald A. Benjamin sold 11,489 shares of the business’s stock in a transaction on Thursday, May 26th. The shares were sold at an average price of $85.47, for a total value of $981,964.83. Following the sale, the executive vice president now owns 95,616 shares of the company’s stock, valued at $8,172,299.52. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 1.00% of the stock is currently owned by insiders.
Institutional Trading of Henry Schein
Institutional investors have recently made changes to their positions in the business. Victory Capital Management Inc. lifted its position in shares of Henry Schein by 15.0% in the fourth quarter. Victory Capital Management Inc. now owns 69,916 shares of the company’s stock worth $5,421,000 after purchasing an additional 9,123 shares in the last quarter. DekaBank Deutsche Girozentrale increased its holdings in Henry Schein by 2.1% during the fourth quarter. DekaBank Deutsche Girozentrale now owns 401,956 shares of the company’s stock worth $31,326,000 after buying an additional 8,386 shares during the last quarter. Banque Pictet & Cie SA acquired a new position in Henry Schein during the fourth quarter worth $2,097,000. TCW Group Inc. increased its holdings in Henry Schein by 9.6% during the first quarter. TCW Group Inc. now owns 17,262 shares of the company’s stock worth $1,505,000 after buying an additional 1,514 shares during the last quarter. Finally, Assenagon Asset Management S.A. increased its holdings in Henry Schein by 1,360.3% during the fourth quarter. Assenagon Asset Management S.A. now owns 67,555 shares of the company’s stock worth $5,238,000 after buying an additional 62,929 shares during the last quarter. Institutional investors own 94.30% of the company’s stock.
Henry Schein Company Profile
Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.
- Get a free copy of the StockNews.com research report on Henry Schein (HSIC)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
- Why Apple Could Be At All-Time Highs By Year End
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.